Bausch & Lomb to license Plasmin for ophthalmic use
Bayer HealthCare, Biological Products Division, has granted Bausch & Lomb an exclusive worldwide license for its Plasmin technology for use in ophthalmology.
Bayer HealthCare, Biological Products Division, has granted Bausch & Lomb an exclusive worldwide license for its Plasmin technology for use in ophthalmology.
Under the terms of the agreement, Bausch & Lomb will be responsible for the development of Plasmin, which is derived from processed human plasma, for use in ophthalmology, making milestone payments based on the development and registration progress and paying ongoing royalties based on product sales. Further details of the agreement are confidential.
Bayer is pursuing the development of Plasmin in non-ocular indications where it could be used as a thrombolytic agent.